Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03201965 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 416
- Enrollment target
NCT03201965 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 416 participants.
The verdict
NCT03201965, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 416 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Interventions
- DRUG Cyclophosphamide
- DRUG Daratumumab
- DRUG Bortezomib
- DRUG Dexamethasone, 40 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 416 participants |
| Start Date | 2017-10-05 |
| Est. Completion | 2024-11-19 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03201965
The ClinicalTrials.gov registry entry for NCT03201965 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 416 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT03201965 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03201965 about?
NCT03201965 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis". The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
What is the current status of trial NCT03201965?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 416 participants. The study started on 2017-10-05. Estimated completion is 2024-11-19.
What interventions are being tested in trial NCT03201965?
The interventions under investigation include: Cyclophosphamide (DRUG), Daratumumab (DRUG), Bortezomib (DRUG), Dexamethasone, 40 mg (DRUG).
Who is sponsoring clinical trial NCT03201965?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.